TEVA.TA
TEVA.TA
IL0006290147
TEVA PHARMA IND
Loading chart...
Elevated Business & Solvency Risk

Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 50/100).

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.8x).

Beta (Market Relation)
0.82x
Defensive
Volatility (5Y p.a.)
44.2% p.a.
5-Year Horizon
Max Drawdown (5Y)
-40.5%
5-Year Horizon
Sharpe Ratio
0.60
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +75.4%
3 Years 40.3% -40.5% 1.14 +48.3%
5 Years 44.2% -40.5% 0.6 +29.2%
10 Years 49.9% -87.4% -0.13 -3.8%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 218%.
🔴 High valuation risk: Avg P/E of 62.8 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (44.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -87.4% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
4 ISS Score: 4 / 10
Audit Risk
8 ISS Score: 8 / 10
Board Risk
3 ISS Score: 3 / 10
Short Ratio
-
ende